Tirzepatide tied to fewer joint infections than semaglutide at two years

The wire

1. 01A TriNetX retrospective cohort matched 2,858 tirzepatide and 2,858 semaglutide patients after primary TKA or THA; at two years tirzepatide had lower odds of mechanical complications (OR 0.64) and periprosthetic joint infection (OR 0.64, P=.048).
2. 02Surgeons and perioperative teams increasingly see incretin users; the data suggest no short-term outcome penalty for either agent through one year.
3. 03Retrospective claims-network design, only 1.3% of 669,698 arthroplasty patients had two or more fills, and the authors call the two-year findings preliminary associations needing larger cohorts.

From the source

Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026 Oct 21 · Davis SC, Patel SV, Fletcher S et al.